CardioRisk IndiaSimulation Module · Phase 1 liveDeterministic · No LLM in core · Reproducible on rng_seed
Indians present with MI a decade earlier than the West. CardioRisk India models the cardiac risk Indian patients actually die from.
Six simulation engines wired against Indian-frequency-weighted CPIC tables: clopidogrel active-metabolite response (CYP2C19), statin myopathy (SLCO1B1), IWPC warfarin dosing (CYP2C9 × VKORC1), Lp(a) test-recommendation, Monte-Carlo Indian-cohort MI-risk distribution, and directional SINAM scenario (HLA-DRB1*11:01). Every number traces to a curated table entry — auditable at /api/cardiorisk/factors.
The India gap in one glance
~10 yr
earlier MI onset vs West (mean ~50yo, CADI-Kerala / CREATE)
23%
CYP2C19*2 in Indians — clopidogrel non-response after PCI
18%
NUDT15 c.415C>T — pediatric leukemia dose-critical
~25%
Indians with Lp(a) >50 mg/dL, systematically under-tested
68%
CYP3A5 *3/*3 — post-transplant tacrolimus dose gap
Frequencies: PGX_RULES (IndiGen + published Indian cohort literature). Some numbers carry
verification_required=true — see /methods.CYP2C19 → clopidogrel active-metabolitePERTURBATION
Given a CYP2C19 diplotype, resolve phenotype, apply CPIC 2022 activity factor to baseline active-metabolite exposure. HTPR-flag intermediate/poor metabolizers, recommend prasugrel/ticagrelor per CPIC.